<i>In vivo</i>brain microdialysis to evaluate FITC-dextran encapsulated immunopegylated nanoparticles

Bommana, Murali Mohan; Kirthivasan, Bharat; Squillante, Emilio

doi:10.3109/10717544.2012.714812

Cited by 13 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to demonstrating brain parenchymal entry, the capillary depletion method suggested nearly all of 5-nm ceria in the brain was associated with the capillary endothelial cells, consistent with EM observations of nanoceria adhered to the luminal side of blood vessel walls in the brain, noted above [21]. NP components have been sampled from the brain using microdialysis probes [74][75][76][77]. In the presence of an intact BBB, it is assumed that this technique samples brain extracellular space.…”

Section: Methods To Demonstrate Np Brain Parenchymal Entrymentioning

confidence: 82%

Nanoparticle Brain Delivery: A Guide to Verification Methods

Yokel

2020

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Many reports conclude nanoparticle (NP) brain entry based on bulk brain analysis. Bulk brain includes blood, cerebrospinal fluid and blood vessels within the brain contributing to the blood–brain and blood–cerebrospinal fluid barriers. Considering the brain as neurons, glia and their extracellular space (brain parenchyma), most studies did not show brain parenchymal NP entry. Blood–brain and blood–cerebrospinal fluid barriers anatomy and function are reviewed. Methods demonstrating brain parenchymal NP entry are presented. Results demonstrating bulk brain versus brain parenchymal entry are classified. Studies are reviewed, critiqued and classified to illustrate results demonstrating bulk brain versus parenchymal entry. Brain, blood and peripheral organ NP timecourses are compared and related to brain parenchymal entry evidence suggesting brain NP timecourse informs about brain parenchymal entry.

show abstract

Section: Methods To Demonstrate Np Brain Parenchymal Entrymentioning

confidence: 82%

Nanoparticle Brain Delivery: A Guide to Verification Methods

Yokel

2020

Nanomedicine (Lond.)

View full text Add to dashboard Cite

show abstract

“…PLGA PNPs encapsulating the opioid tetrapeptide, endomorphin, were conjugated with the OX26 antibody, and the effect on analgesia was tested in rats [898]. Pegylated PLA PNPs were conjugated with the OX26 antibody and BBB transport was demonstrated by cerebral microdialysis in rats [899]. Pegylated mesoporous silica nanoparticles were conjugated with the rat RI7-217 antibody against the mouse TfR, and BBB transport was demonstrated in cell culture using the mouse bEND5 cells and in vivo in the mouse using fluorescent microscopy [900].…”

Section: Receptor-mediated Transport Of Nanoparticlesmentioning

confidence: 99%

A Historical Review of Brain Drug Delivery

Pardridge

2022

Pharmaceutics

106

View full text Add to dashboard Cite

The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914, that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood–brain barrier (BBB). Owing to restricted transport across the BBB, FDA-approved drugs for the CNS have been generally limited to lipid-soluble small molecules. Drugs that do not cross the BBB can be re-engineered for transport on endogenous BBB carrier-mediated transport and receptor-mediated transport systems, which were identified during the 1970s–1980s. By the 1990s, a multitude of brain drug delivery technologies emerged, including trans-cranial delivery, CSF delivery, BBB disruption, lipid carriers, prodrugs, stem cells, exosomes, nanoparticles, gene therapy, and biologics. The advantages and limitations of each of these brain drug delivery technologies are critically reviewed.

show abstract

“…PEG itself has been combined with chitosan to produce nanoparticles that could deliver anti-caspase peptides to the brain using the OX26 antibody as a targeting molecule (Aktaş et al, 2005;Yemisci et al, 2015;2012). OX26 has also been used to target both poly-lactic acid (PLA)-PEG, PEG-polycaprolactone (PCL), and poly(lactic-co-glycolic acid) (PLGA) nanoparticles to the brain, hereby delivering amphotecirin B, Aß peptide, temozolomide, and Tempol across the endothelial layer (Bommana et al, 2012;Carroll et al, 2010;Loureiro et al, 2016;Pang et al, 2008;Ramalho et al, 2018;Sriramoju et al, 2015;Tang et al, 2015). The anti-mouse TfR antibody variants, 8D3 and RI7, were also used to target polymer nanoparticles towards the brain (Bhattacharya et al, 2008;Papademetriou et al, 2013).…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%